lenalidomide has been researched along with Acute Myelogenous Leukemia in 119 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (6.72) | 29.6817 |
| 2010's | 85 (71.43) | 24.3611 |
| 2020's | 26 (21.85) | 2.80 |
| Authors | Studies |
|---|---|
| Abedi, M; Hoeg, R; Krishnan, R; Pham, B; Richman, C; Tuscano, J | 1 |
| Brenizer, T; Deal, AM; Foster, MC; Ivanova, A; Jamieson, K; Matson, M; Muss, H; Nyrop, KA; Pulley, W; Van Deventer, HW; Vohra, SN; Woods, JD; Zeidner, JF; Zhang, J | 1 |
| Bernard, E; Cavelier, L; Dybedal, I; Ebeling, F; Ejerblad, E; Flogegård, M; Garelius, H; Göhring, G; Grønbaek, K; Hellström-Lindberg, E; Jädersten, M; Kittang, AO; Lorenz, F; Marcher, CW; Möllgård, L; Nilsson, L; Nørgaard, JM; Öster Fernström, A; Papaemmanuil, E; Rasmussen, B; Saft, L; Tobiasson, M | 1 |
| Chandar, R; Meena, S; Raj, R; Ramakrishnan, B; Uppuluri, R; Varla, H; Vellaichamy Swaminathan, V | 1 |
| Adès, L; Amé, S; Benramdane, R; Beyne-Rauzy, O; Bordessoule, D; Braun, T; Chermat, F; Chevret, S; Cheze, S; Cluzeau, T; de Botton, S; Dimicoli-Salazar, S; Duployez, N; Fenaux, P; Guerci-Bresler, A; Laribi, K; Marolleau, JP; Nimubona, S; Park, S; Peterlin, P; Preudhomme, C; Quesnel, B; Recher, C; Stamatoullas, A; Thepot, S; Toma, A; Vey, N; Wattel, E; Wickenhauser, S; Zerazhi, H | 1 |
| Buzoianu, AD; Ciechanover, A; Dima, D; Drula, R; Ghiaur, G; Gulei, D; Iluta, S; Iuga, C; Tomuleasa, C | 1 |
| Ichikawa, M | 2 |
| Astolfi, A; Boultwood, J; Casalin, I; Cavo, M; Cocco, L; De Stefano, A; Finelli, C; Follo, MY; Indio, V; Manzoli, L; McCubrey, JA; Mongiorgi, S; Paolini, S; Parisi, S; Pellagatti, A; Pession, A; Ratti, S; Suh, PG | 1 |
| Sallman, DA; Wang, C | 1 |
| Cadeddu, RP; Christopeit, M; Drusenheimer, N; Esseling, E; Germing, U; Haas, R; Holtick, U; Jäger, P; Klein, S; Kobbe, G; Kröger, N; Mikesch, JH; Rautenberg, C; Scheid, C; Schroeder, T; Stelljes, M; Trenschel, R | 1 |
| Garcia-Manero, G | 2 |
| Bulach, C; Götz, M; Greiner, J; Guinn, BA; Hofmann, S; Schrezenmeier, H; Schuler, PJ; Weiss, J | 1 |
| Aoki, Y; Minehata, K; Motegi, Y; Uno, S | 1 |
| Bixby, D; Burke, PW; Crouch, A; Erba, HP; Marini, BL; Merz, LE; Perissinotti, AJ | 1 |
| Ballen, K; Bhatt, S; Brunner, A; Burgess, M; Carr, SA; DeAngelo, DJ; Ebert, BL; Fell, G; Garcia, JS; Keshishian, H; Letai, A; Medeiros, BC; Neuberg, D; Sperling, AS; Stone, RM; Yilma, B | 1 |
| A von dem Borne, P; Bargetzi, M; Biemond, BJ; Breems, DA; Chalandon, Y; Cloos, J; de Jongh, E; de Weerdt, O; Deeren, D; Fehr, M; Gjertsen, B; Graux, C; Huls, G; Janssen, JJJW; Jaspers, A; Jongen-Lavrencic, M; Klein, SK; Löwenberg, B; Maertens, J; Manz, M; Michaux, L; Ossenkoppele, GJ; Pabst, T; Stuessi, G; Tick, L; Valk, P; van der Klift, M; van der Poel, MWM; van der Velden, WJFM; van Marwijk Kooy, M; van Norden, Y; van Rhenen, A; Vekemans, MC | 1 |
| Michel, RP; Monczak, Y; Sebag, M; Shustik, C; Waller, DD | 1 |
| Menssen, AJ; Walter, MJ | 1 |
| Dou, A; Fang, J; Feng, S; Halene, S; Hawkins, C; He, X; Lawley, L; Mizukawa, B; Patel, A; Roman-Rivera, A; Wunderlich, M; Zhang, J | 1 |
| Greenberg, P; Hellström-Lindberg, E; Tobiasson, M | 1 |
| Abou Dalle, I; Andreeff, M; Borthakur, G; Cortes, JE; Daver, N; DiNardo, CD; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Jabbour, E; Jain, N; Jammal, N; Kadia, TM; Kantarjian, HM; Naqvi, K; Pelletier, S; Pemmaraju, N; Pierce, S; Ravandi, F; Wang, SA; Wang, X | 1 |
| Grant, S | 1 |
| Bargetzi, M; Beverloo, B; Biemond, BJ; Breems, DA; Cloos, J; Cornelissen, J; de Weerdt, O; Deeren, D; Fischer, T; Floisand, Y; Gadisseur, A; Gjertsen, BT; Gradowska, P; Graux, C; Gregor, M; Griskevicius, L; Höglund, M; Hoogendoorn, M; Huls, G; Janssen, JJWM; Jongen-Lavrencic, M; Juliusson, G; Klein, SK; Kuball, J; Legdeur, MJC; Löwenberg, B; Maertens, J; Manz, MG; Meyer, P; Michaux, L; Moors, I; Ossenkoppele, GJ; Pabst, T; Passweg, J; Porkka, K; Silzle, T; Spertini, O; Tick, LW; Valk, PJM; van der Velden, WJFM; van Elssen, CHMJ; van Esser, JWJ; van Lammeren-Venema, D; van Marwijk Kooy, M; Veelken, H; Vekemans, MC; Vellenga, E; Westerweel, PE | 1 |
| Banz, Y; Bargetzi, M; Brune, MM; Cogliatti, S; Fehr, M; Grobholz, R; Haralambieva, E; Heim, D; Li, Q; Löwenberg, B; Lundberg, P; Manz, MG; Mazzuchelli, L; Medinger, M; Ossenkoppele, GJ; Pabst, T; Passweg, J; Rudolf, CB; Stüssi, G; Tzankov, A; Vela, V | 1 |
| Chen, L; Cheng, C; Li, D; Mi, R; Wei, X | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Banos, A; Béné, MC; Bernard, M; Bonmati, C; Bouscary, D; Carré, M; Choufi, B; Couturier, MA; Daguindau, E; Delaunay, J; Dreyfus, F; Fornecker, LM; Hamel, JF; Himberlin, C; Hunault-Berger, M; Ifrah, N; Lissandre, S; Luquet, I; Maillard, N; Marolleau, JP; Ojeda-Uribe, M; Orsini-Piocelle, F; Pigneux, A; Puyade, M; Recher, C; Rouillé, V; Saad, A; Sanhes, L; Schmidt-Tanguy, A; Sutton, L; Tavernier, E | 1 |
| Bug, G; Fabarius, A; Fey, S; Ganser, A; Germing, U; Giagounidis, A; Götze, K; Haase, D; Haferlach, C; Hofmann, WK; Jann, JC; Letsch, A; Lübbert, M; Mossner, M; Nolte, F; Nowak, D; Nowak, V; Obländer, J; Palme, I; Platzbecker, U; Pressler, J; Schlenk, R; Xanthopoulos, C | 1 |
| Beyne-Rauzy, O; Deeg, HJ; Del Cañizo, C; Fenaux, P; Giagounidis, A; Greenberg, PL; Guerci-Bresler, A; Hellström-Lindberg, E; List, AF; Mittelman, M; Muus, P; Nimer, SD; Powell, BL; Sekeres, MA; Selleslag, D; Shammo, JM; Skikne, B; Yu, X | 1 |
| Cohen, PL; Debonera, F; Kremer, B; Schuster, SJ; Tsai, DE | 1 |
| Cortelezzi, A; Fattizzo, B; Ferla, V; Fracchiolla, NS; Freyrie, A; Iurlo, A; Reda, G | 1 |
| Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N | 1 |
| Di Raimondo, F; Ferrara, F; Fuligni, F; Isidori, A; Loscocco, F; Paolini, S; Piccaluga, PP; Rocchi, M; Spina, E; Visani, A; Visani, G; Zammit, V | 1 |
| Beach, CL; Gale, RP; Kambhampati, S; Kew, A; Kumar, R; McCaul, K; Medeiros, BC; Pollyea, DA; Saini, L; Silverman, LR; Vij, R; Wang, X; Zhong, J | 1 |
| Amrein, PC; Attar, EC; Avigan, D; Ballen, KK; Brunner, AM; DeAngelo, DJ; Ebert, BL; Fathi, AT; Hobbs, GS; Luptakova, K; McMasters, M; Rosenblatt, J; Sperling, AS; Steensma, DP; Stone, RM; Stroopinsky, D; Wadleigh, M; Washington, A; Werner, L | 1 |
| Ebert, BL; Fenaux, P; List, A | 1 |
| Bansal, D; Chang, GS; DiPersio, JF; Fehniger, TA; Heath, SE; Miller, CA; Vij, K; Vij, R; Welch, JS; Westervelt, P | 1 |
| Arcioni, F; Covezzoli, A; Cundari, S; Di Battista, V; Mecucci, C; Roncadori, A; Tura, S | 1 |
| Ben Amara, A; Benyamine, A; Castanier, C; Castellano, R; Collette, Y; Fauriat, C; Fournié, JJ; Goubard, A; Granjeaud, S; Le Roy, A; Mege, JL; Olive, D; Orlanducci, F; Pont, F; Prébet, T; Riccardi, F; Vey, N | 1 |
| Chen, YB; Dey, BR; Fathi, AT; Hobbs, G | 1 |
| Döhner, H; Fiedler, W; Hütter-Krönke, ML; Krauter, J; Kündgen, A; Schlenk, RF; von Lilienfeld-Toal, M | 1 |
| Brock, K; Cavenagh, J; Craddock, C; De Santo, C; Dennis, M; Ferguson, P; Hodgkinson, A; Ingram, W; Malladi, R; Mussai, F; Siddique, S; Slade, D; Wheat, R; Yap, C | 1 |
| Blum, KA; Blum, W; Byrd, JC; Foster, DJR; Gao, Y; Grever, MR; Hofmeister, CC; Hughes, JH; Marcucci, G; Phelps, MA; Reuter, SE; Upton, RN | 1 |
| Abbasi, T; Abbott, D; Cogle, CR; Drusbosky, L; Fullerton, A; Gutman, JA; Hammes, A; Hemenway, G; Jordan, CT; Miltgen, N; Pollyea, DA; Schatz, D; Singh, NK; Smith, C; Stevens, B; Vali, S; Wei, Q; Winters, A | 1 |
| Kunacheewa, C; Owattanapanich, W; Thongthang, P; Ungprasert, P; Utchariyaprasit, E | 1 |
| Bewersdorf, JP; Stahl, M; Zeidan, AM | 1 |
| Estey, EH; Percival, MM | 1 |
| Germing, U; Platzbecker, U | 1 |
| Amrein, PC; Attar, EC; Ballen, KK; Deangelo, DJ; Fathi, AT; Foster, J; Fraser, JW; McAfee, S; Neuberg, D; Steensma, DP; Stone, RM; Wadleigh, M | 1 |
| Fenaux, P; Germing, U; Giagounidis, A; List, A; MacBeth, KJ; Mufti, GJ | 1 |
| Bennett, JM; Fu, T; Giagounidis, A; Knight, RD; List, AF; Nimer, SD; Sekeres, MA; Shammo, JM; Skikne, B | 1 |
| Caraci, MR; Di Raimondo, F; Ferrara, F; Fuligni, F; Gazzola, A; Isidori, A; Laginestra, MA; Loscocco, F; Paolini, S; Piccaluga, PP; Pileri, SA; Riccardi, C; Rocchi, M; Rossi, M; Sparaventi, G; Visani, A; Visani, G | 1 |
| Tohyama, K | 1 |
| Besa, EC; Gaballa, MR | 1 |
| Bhagat, T; Braunschweig, I; Roth, M; Schinke, C; Steidl, U; Tamari, R; Verma, A; Will, B | 1 |
| Govindaraj, C; Kong, YY; Madondo, M; Plebanski, M; Tan, P; Wei, A | 1 |
| Wiernik, PH | 1 |
| Benettaib, B; Beyne-Rauzy, O; Bowen, D; del Cañizo, C; Fenaux, P; Fu, T; Ganser, A; Giagounidis, A; Göhring, G; Guerci-Bresler, A; Hellström-Lindberg, E; Lübbert, M; Mittelman, M; Mufti, GJ; Muus, P; Nilsson, L; Platzbecker, U; Quesnel, B; Sanz, G; Schlegelberger, B; Selleslag, D; te Boekhorst, P | 1 |
| Schleiffenbaum, BE | 1 |
| Abe, Y; Hamano, A; Hattori, Y; Miyazaki, K; Nakagawa, Y; Sekine, R; Shingaki, S; Suzuki, K; Tsukada, N | 1 |
| Dimopoulos, MA; Dispenzieri, A; Gertz, MA; Kastritis, E; Kumar, S; Orlowski, R; Shah, J; Shah, RA; Terpos, E | 1 |
| Avery, S; Fleming, S; Govindaraj, C; McManus, J; Patil, S; Perruzza, S; Plebanski, M; Spencer, A; Stevenson, W; Tan, P; Wei, A | 1 |
| Foster, MC; Lim, MY; Raval, JS; Richards, KL; Zeidner, JF | 1 |
| Mukherjee, S; Ornstein, MC; Sekeres, MA | 1 |
| Foster, MC; Zeidner, JF | 1 |
| Bellotti, D; Boiocchi, L; Borlenghi, E; Cerqui, E; Imberti, L; Lamorgese, C; Pagani, C; Pelizzari, A; Rossi, G; Schieppati, F; Sottini, A | 1 |
| Champlin, RE; Pingali, SR | 1 |
| Breier, A; Coculova, M; Imrichova, D; Kavcova, H; Messingerova, L; Pavlikova, L; Seres, M; Sulova, Z | 1 |
| Braulke, F; Ganster, C; Haase, D; Platzbecker, U; Salinas-Riester, G; Schanz, J; Shirneshan, K | 1 |
| Aylı, M; Cengiz Seval, G; Özcan, M | 1 |
| Berube, C; Cardone, MH; Coutre, S; Doykan, C; Garcia, JS; Gotlib, J; Greenberg, P; Hewitt, R; Liedtke, M; McMillan, A; Medeiros, BC; Narayan, R; Percival, ME; Regan, K; Williamson, C | 1 |
| Al Ali, NH; Bart-Smith, E; Craig, BM; Epling-Burnette, PK; Komrokji, RS; Kordasti, S; Kulasekararaj, A; Lancet, JE; List, AF; Mufti, GJ; Padron, E; Pinilla-Ibarz, J; Zhang, L | 1 |
| Brady, WE; Dickey, NM; Ford, LA; Griffiths, EA; L Bashaw, H; Sperrazza, J; Tan, W; Thompson, JE; Vigil, CE; Wang, ES; Wetzler, M | 1 |
| Al Ali, NH; Dalton, W; Fisher, K; Fulp, W; Hampras, SS; Kenvin, L; Knight, R; Komrokji, RS; Lancet, J; Lee, JH; List, A; Olesnyckyj, M; Padron, E; Rollison, DE; Shain, KH; Xu, Q | 1 |
| Barker, B; Bolanos, L; Cortelezzi, A; Cuzzola, M; Fang, J; Fontanillo, C; Grimes, HL; Komurov, K; Liu, X; MacBeth, K; Oliva, EN; Rigolino, C; Starczynowski, DT | 1 |
| Ma, LM; Ruan, LH; Yang, XW; Zhao, XQ | 1 |
| Carraway, HE; DeZern, A; Gojo, I; Gore, SD; Smith, BD; Zeidan, AM | 1 |
| Ando, T; Kimura, S; Kizuka, H; Kojima, K; Kubota, Y; Kusaba, K; Nishioka, A; Sano, H; Shindo, T; Ureshino, H | 1 |
| Stahl, M; Zeidan, AM | 1 |
| Nohgawa, M; Oka, S; Ono, K | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Abboud, CN; Blum, W; Byrd, JC; Fehniger, TA; Kefauver, C; Marcucci, G; Payton, JE; Vij, R | 1 |
| Cantalapiedra, A; Conde, J; Garcia Frade, LJ; Peñarrubia, MJ; Silvestre, LA | 1 |
| Hanson, CA; Ketterling, RP; Knudson, RA; Mesa, RA; Schwager, S; Tefferi, A | 1 |
| Gore, SD | 1 |
| Hussein, K; Tefferi, A | 1 |
| Asch, J; Ford, CD; Konopa, K; Petersen, FB | 1 |
| Adès, L; Boehrer, S; Eclache, V; Fenaux, P; Gardin, C; Leroux, G; Martiat, P | 1 |
| List, A | 1 |
| Aul, C; Büsche, G; Giagounidis, A; Göhring, G; Hellström-Lindberg, E; Kreipe, HH; Schlegelberger, B; Zimmermann, M | 1 |
| Dufva, IH; Risum, M | 1 |
| Hofmann, WK; Nolte, F | 1 |
| Becker, H; Blum, W; Byrd, JC; Chandler, JC; Curfman, J; Devine, SM; Garzon, R; Grever, MR; Kefauver, C; Klisovic, RB; Liu, S; Marcucci, G; Mickle, J; Phelps, MA; Rozewski, DM; Schaaf, L; Walker, A; Whitman, SP; Yang, X | 1 |
| Abboud, CN; Cashen, AF; Demland, J; DiPersio, JF; Fehniger, TA; Nelson, AD; Stockerl-Goldstein, KE; Trinkaus, K; Uy, GL; Vij, R; Westervelt, P | 1 |
| Baer, MR; Gojo, I | 1 |
| Bello, C; Komrokji, RS; Lancet, JE; List, AF; Wetzstein, GA; Yu, D; Zhu, W | 1 |
| Sanchez, JF | 1 |
| Advani, A; Appelbaum, FR; Gundacker, H; Lancet, J; Liesveld, J; List, AF; Mulford, D; Norwood, T; Petersdorf, S; Sekeres, MA; Willman, CL | 1 |
| Astermark, J; Dufva, IH; Dybedal, I; Ejerblad, E; Garelius, H; Grønbæk, K; Hellström-Lindberg, E; Jädersten, M; Jansson, M; Kjeldsen, L; Lindberg, EH; Linder, O; Möllgård, L; Nilsson, L; Nørgaard, JM; Porwit, A; Saft, L; Treppendahl, MB; Vestergaard, H | 1 |
| Komrokji, RS; List, AF | 1 |
| Gorin, NC; Isnard, F; Malak, S; Perot, C; Rubio, MT; Scherman, E | 1 |
| Abdel-Wahab, O; Berube, C; Bhattacharya, S; Coutre, S; Figueroa, ME; Gallegos, L; Gotlib, JR; Kohrt, HE; Levine, R; Liedtke, M; Medeiros, BC; Melnick, A; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B | 1 |
| Afable, M; Guinta, K; Jankowska, A; Jerez, A; List, AF; Maciejewski, J; Makishima, H; McGraw, KL; O'Keefe, CL; Sekeres, MA; Sugimoto, Y; Szpurka, H; Tiu, R; Traina, F; Visconte, V | 1 |
| Matsuoka, A; Tohyama, K; Tohyama, Y; Tsujioka, T | 1 |
| Borthakur, G; Chen, Y; Cortes, J; Estrov, Z; Faderl, S; Kantarjian, H; Ravandi, F; Rey, K | 1 |
| Lentzsch, S; Pan, B | 1 |
| Abboud, CN; Bernabe, N; Cashen, AF; DiPersio, JF; Monahan, R; Ramsingh, G; Stockerl-Goldstein, K; Uy, GL; Vij, R; Westervelt, P | 1 |
| Brower, V | 1 |
| Medeiros, BC; Ungewickell, A | 1 |
| Giagounidis, AA | 1 |
| Alachkar, H; Becker, H; Bloomfield, CD; Blum, W; Byrd, JC; Caligiuri, MA; Dorrance, AM; Eiring, AM; Fehniger, TA; Garzon, R; Hickey, CJ; Lee, LJ; Maharry, K; Marcucci, G; Mishra, A; Mrózek, K; Nicolet, D; Perrotti, D; Radomska, HS; Santhanam, R; Schwind, S; Vij, R; Walker, A; Whitman, SP; Wu, LC; Wu, YZ; Zhao, X | 1 |
| Blaise, D; Charbonnier, A; Gelsi-Boyer, V; Mozziconacci, MJ; Prebet, T; Vey, N | 1 |
| Backstrom, J; Brandenburg, NA; Fenaux, P; Germing, U; Giagounidis, AA; Glasmacher, A; Hasford, J; Kuendgen, A; Lauseker, M; List, AF | 1 |
| Suzuki, K | 1 |
| Borthakur, G; Chen, Y | 1 |
| Bornhäuser, M; Braulke, F; Bug, G; Ehninger, G; Germing, U; Giagounidis, A; Götze, K; Haase, D; Hofmann, WK; Kündgen, A; Naumann, R; Neesen, J; Platzbecker, U; Röllig, C; Schönefeldt, C; Shirneshan, K; Wermke, M | 1 |
| Bauters, F; Berthon, C; Facon, T; Guieze, R; Kuhnovsky, F; Leleu, X; Micol, JB; Moreau, AS; Terriou, L; Yakoub-Agha, I | 1 |
32 review(s) available for lenalidomide and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML.
Topics: Bortezomib; Deubiquitinating Enzymes; Drug Discovery; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Proteasome Endopeptidase Complex; Thalidomide; Ubiquitin | 2022 |
Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes.
Topics: Anemia; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life | 2023 |
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Topics: Aged; Bone Marrow; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis | 2023 |
Genetics of progression from MDS to secondary leukemia.
Topics: Cell Count; Clonal Evolution; Disease Progression; DNA Methylation; DNA Mutational Analysis; Epigenesis, Genetic; Exome Sequencing; Hematopoietic Stem Cells; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Myelopoiesis; Neoplastic Stem Cells; Prognosis; Tumor Burden; Whole Genome Sequencing | 2020 |
Myelodysplastic syndromes: moving towards personalized management.
Topics: Anemia; Erythropoiesis; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2020 |
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin | 2017 |
A decade of progress in myelodysplastic syndrome with chromosome 5q deletion.
Topics: Animals; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Management; Disease Progression; Drug Development; Genetic Heterogeneity; Genetic Predisposition to Disease; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Prognosis; Treatment Outcome; Tumor Suppressor Protein p53 | 2018 |
A systematic review and meta
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Female; Hematologic Diseases; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2019 |
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Topics: Angiogenesis Inhibitors; Apoptosis; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Clone Cells; Disease Progression; Erythropoiesis; Gene Dosage; Genes, Tumor Suppressor; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2014 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Gene Expression; Haploinsufficiency; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; MicroRNAs; Myelodysplastic Syndromes; Practice Guidelines as Topic; Ribosomal Proteins; Thalidomide; Tumor Suppressor Protein p53 | 2014 |
Optimal therapy for adult patients with acute myeloid leukemia in first complete remission.
Topics: Adenine Nucleotides; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Humans; Interleukin-2; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Stem Cell Transplantation; Thalidomide; Treatment Outcome; Young Adult | 2014 |
More is better: combination therapies for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progression; Drug Therapy, Combination; Gene Expression; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines; Thalidomide; Valproic Acid; Vorinostat | 2015 |
Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Thalidomide; Treatment Outcome | 2017 |
Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.
Topics: Allografts; Bortezomib; Chemoradiotherapy; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Transplantation Conditioning | 2015 |
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Disease Management; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Karyotype; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Research Design; Thalidomide; Transplantation, Homologous | 2015 |
5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 5; Fatal Outcome; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Translocation, Genetic | 2017 |
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
Topics: Anemia; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 5; Disease Progression; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2017 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
Topics: Antineoplastic Agents; Chromosome Deletion; Clinical Trials as Topic; Disease Progression; Humans; Immunosuppression Therapy; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Medical Oncology; Myelodysplastic Syndromes; Risk; Thalidomide; Treatment Outcome | 2009 |
[Current treatment options for myelodysplastic syndromes].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Blood Transfusion; Bone Marrow Transplantation; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Iron Overload; Lenalidomide; Leukemia, Myeloid, Acute; Long-Term Care; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Thalidomide | 2010 |
Treatment of myelodysplastic syndromes in elderly patients.
Topics: Aged; Anemia, Macrocytic; Antineoplastic Agents; Azacitidine; Blood Component Transfusion; Case Management; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Contraindications; Hematinics; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunomodulation; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Palliative Care; Quality of Life; Risk Assessment; Survival Rate; Thalidomide | 2011 |
Role of lenalidomide in the treatment of myelodysplastic syndromes.
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2011 |
Approach to new therapeutics: investigation by the use of MDS-derived cell lines.
Topics: Animals; Cell Line; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Profiling; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide | 2012 |
The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Thalidomide | 2012 |
Novel agents in acute myeloid leukemia.
Topics: Antineoplastic Agents; Aurora Kinases; DNA Modification Methylases; Epigenesis, Genetic; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Protein Serine-Threonine Kinases; Research Design; Thalidomide; Ubiquitin-Activating Enzymes | 2012 |
Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2012 |
Current therapeutic strategy for multiple myeloma.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid | 2013 |
Lenalidomide as a novel treatment of acute myeloid leukemia.
Topics: Angiogenesis Inhibitors; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Thalidomide | 2013 |
[Thalidomide: mechanisms of action and new insights in hematology].
Topics: Amyloidosis; Angiogenesis Inhibitors; Clinical Trials as Topic; Cytokines; Follow-Up Studies; Forecasting; Hematologic Diseases; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrence; Thalidomide; Time Factors; Waldenstrom Macroglobulinemia | 2005 |
35 trial(s) available for lenalidomide and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Transplantation, Homologous | 2021 |
Phase Ib trial of lenalidomide as post-remission therapy for older adults with acute myeloid leukemia: Safety and longitudinal assessment of geriatric functional domains.
Topics: Aged; Antineoplastic Agents; Bayes Theorem; Cohort Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute | 2022 |
"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
Topics: Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Karyotype; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Idarubicin; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Treatment Outcome; Valproic Acid | 2022 |
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytarabine; Etoposide; Female; Humans; Induction Chemotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitochondria; Mitoxantrone | 2020 |
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Remission Induction; Survival Rate | 2020 |
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Middle Aged; Remission Induction; Risk Assessment; Young Adult | 2021 |
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.
Topics: Adolescent; Adult; Aged; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Transplantation, Autologous; Young Adult | 2021 |
Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.
Topics: Aged; Angiogenesis Inhibitors; Bone Marrow; Cohort Studies; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Neovascularization, Pathologic; Tumor Microenvironment | 2021 |
Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.
Topics: Aged; Aged, 80 and over; Azacitidine; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Survival Rate; Thalidomide | 2017 |
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Chromosomes, Human, Pair 5; Cytogenetics; Disease Progression; Erythrocyte Transfusion; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Thalidomide; Treatment Outcome | 2017 |
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Disease-Free Survival; Female; Gene Expression Profiling; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Thalidomide; Transcriptome; Treatment Outcome | 2017 |
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid, Acute; Male; Proportional Hazards Models; Treatment Outcome | 2018 |
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Analysis | 2018 |
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
Topics: Aged; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Immunologic Factors; Italy; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Registries; Remission Induction; Retrospective Studies; Thalidomide | 2018 |
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Recurrence; Salvage Therapy; Stem Cell Transplantation; Time Factors; Transplantation, Homologous; Treatment Failure; United Kingdom; Young Adult | 2019 |
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Computational Biology; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Predictive Value of Tests; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2019 |
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Survival Rate; Thalidomide | 2013 |
Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Prospective Studies; Remission Induction; Thalidomide | 2014 |
Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Drug Therapy, Combination; Gene Expression; Humans; Immunologic Factors; Interferon-gamma; Interleukin-2; Lenalidomide; Leukemia, Myeloid, Acute; Receptors, Tumor Necrosis Factor, Type II; Recurrence; Remission Induction; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Thalidomide | 2014 |
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Disease Progression; Drug Administration Schedule; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mutation; Nucleophosmin; Thalidomide; Treatment Outcome | 2015 |
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; BH3 Interacting Domain Death Agonist Protein; Biomarkers; Bone Marrow; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retreatment; Thalidomide; Treatment Outcome | 2016 |
A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Thalidomide | 2016 |
[Clinical Curative Efficacy of Lenalidomide Combined with Chemotherapy for Acute Leukemia and Its Impact on VEGF].
Topics: Acute Disease; Antineoplastic Agents; Drug Therapy, Combination; Fibroblast Growth Factor 2; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Thalidomide; Vascular Endothelial Growth Factor A | 2016 |
A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.
Topics: Aged; Aged, 80 and over; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Salvage Therapy; Survival Rate; Thalidomide; Treatment Failure; Treatment Outcome | 2017 |
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 13; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Remission Induction; Thalidomide; Trisomy | 2009 |
Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Sialic Acid Binding Ig-like Lectin 3; Thalidomide | 2010 |
A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Cell Count; Cytogenetic Analysis; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Thalidomide; Time Factors; Treatment Outcome | 2011 |
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Thalidomide; Treatment Outcome | 2011 |
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 5; Female; Gene Expression Regulation, Leukemic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Oncogene Protein p21(ras); Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53; WT1 Proteins | 2011 |
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Cytokines; DNA Methylation; Female; Gene Expression Profiling; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Thalidomide; Treatment Outcome | 2012 |
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Risk Factors; Thalidomide; Treatment Outcome | 2012 |
A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Remission Induction; Thalidomide; Young Adult | 2013 |
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2013 |
52 other study(ies) available for lenalidomide and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Post-transplant strategies to improve relapse-free survival in childhood leukemia: Whole blood donor lymphocyte infusions and lenalidomide for inducing graft-versus-leukemia effect.
Topics: Blood Donors; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Lymphocytes; Recurrence; Retrospective Studies | 2022 |
[Updated treatment strategies for myelodysplastic syndromes].
Topics: Antineoplastic Agents; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.
Topics: Azacitidine; DNA Methylation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; MicroRNAs; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-bcl-2 | 2023 |
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial.
Topics: Adult; Azacitidine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphocyte Transfusion; Myelodysplastic Syndromes; Recurrence; T-Lymphocytes; Transplantation, Homologous | 2023 |
A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells.
Topics: Humans; Immunity; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Nivolumab; T-Lymphocytes | 2023 |
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study.
Topics: Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; East Asian People; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Product Surveillance, Postmarketing; Thalidomide; Treatment Outcome | 2023 |
[Current state of treatment for myelodysplastic syndromes].
Topics: Azacitidine; Genome-Wide Association Study; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis | 2023 |
Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Retrospective Studies | 2020 |
Spontaneous remission and clonal evolution in lenalidomide associated secondary AML.
Topics: Clonal Evolution; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Remission Induction; Remission, Spontaneous | 2020 |
Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cyclosporine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Ikaros Transcription Factor; Lenalidomide; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Muscle Proteins; Myelodysplastic Syndromes; Neoplasm Proteins; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Targeting cereblon in AML.
Topics: Humans; Lenalidomide; Leukemia, Myeloid, Acute; Stem Cells; Thalidomide; Ubiquitin-Protein Ligases | 2021 |
Lenalidomide Combined with Interferon α-1b and Interleukin-2 in the Treatment of 21 Cases of Acute Myeloid Leukemia
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Interferon-alpha; Interleukin-2; Lenalidomide; Leukemia, Myeloid, Acute | 2021 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; DNA; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Microsatellite Repeats; Middle Aged; Multiplex Polymerase Chain Reaction; Myelodysplastic Syndromes; Reproducibility of Results; Thalidomide; Uniparental Disomy | 2017 |
Spontaneous remission of acute myeloid leukemia after discontinuation of lenalidomide.
Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission, Spontaneous; Withholding Treatment | 2018 |
Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for.
Topics: Chromosome Deletion; Dendritic Cells; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Plasma Cell; Thalidomide; Treatment Outcome | 2017 |
Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow.
Topics: Aged; Bone Marrow; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Lymphocytes, Tumor-Infiltrating; Mutation; Remission Induction; T-Lymphocytes; Treatment Outcome | 2018 |
Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; CD56 Antigen; Cells, Cultured; Cytotoxicity, Immunologic; Genes, MHC Class I; Humans; Immunologic Factors; K562 Cells; Killer Cells, Natural; Lenalidomide; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Monitoring, Immunologic; Natural Cytotoxicity Triggering Receptor 3; Thalidomide; Xenograft Model Antitumor Assays | 2018 |
Lenalidomide combined with mismatched microtransplantation for acute myeloid leukemia.
Topics: Aged; Allografts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Drug Evaluation; Fatal Outcome; Female; Genes, sry; Histocompatibility; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Peripheral Blood Stem Cell Transplantation; Transplantation Chimera | 2018 |
Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Drug Resistance, Neoplasm; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Recurrence; Retreatment; Treatment Outcome | 2019 |
Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.
Topics: Administration, Oral; Adult; Aged; B-Lymphocytes; Biological Availability; Clinical Trials, Phase I as Topic; Creatinine; Datasets as Topic; Dose-Response Relationship, Drug; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Biological; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Renal Elimination; Young Adult | 2019 |
One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic
Topics: Antigens, CD; Azacitidine; CD8-Positive T-Lymphocytes; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Lymphocyte Activation Gene 3 Protein; Male; Middle Aged; Myelodysplastic Syndromes; Programmed Cell Death 1 Receptor; Recurrence; Transplantation, Homologous | 2019 |
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
Topics: Aged; Chromosome Deletion; Disease Progression; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Survival Analysis; Thalidomide | 2014 |
Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Benzoates; Cell Line, Tumor; Cell Proliferation; Clonal Evolution; Female; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Megakaryocyte Progenitor Cells; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Thalidomide; Thrombopoiesis | 2014 |
[CME myelodysplasia - a frequent hematologic neoplasia in the elderly].
Topics: Aged, 80 and over; Anemia, Aplastic; Azacitidine; Bone Marrow; Bone Marrow Examination; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; Diagnosis, Differential; Disease Progression; Hematopoiesis; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Thalidomide | 2014 |
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Immunosuppressive Agents; Lenalidomide; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyrazines; Retrospective Studies; Thalidomide; Time Factors | 2014 |
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents.
Topics: Acute Disease; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2015 |
Lenalidomide-associated hemolytic anemia.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunosuppressive Agents; Lenalidomide; Leukemia, Myeloid, Acute; Male; Thalidomide; Treatment Outcome | 2015 |
Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Comorbidity; Disease Progression; Erythrocyte Transfusion; Female; Follow-Up Studies; Gene Expression; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prognosis; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53 | 2015 |
Selection of resistant acute myeloid leukemia SKM-1 and MOLM-13 cells by vincristine-, mitoxantrone- and lenalidomide-induced upregulation of P-glycoprotein activity and downregulation of CD33 cell surface exposure.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Down-Regulation; Gene Silencing; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Mitoxantrone; Sialic Acid Binding Ig-like Lectin 3; Thalidomide; Up-Regulation; Vincristine | 2015 |
Influence of total genomic alteration and chromosomal fragmentation on response to a combination of azacitidine and lenalidomide in a cohort of patients with very high risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Female; Humans; Kaplan-Meier Estimate; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Thalidomide; Tumor Suppressor Protein p53 | 2015 |
Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.
Topics: Aged; Aspergillosis; Blood Transfusion; Danazol; Disease Progression; Drug Resistance; Fatal Outcome; Humans; Hydroxyurea; Janus Kinase 2; Lenalidomide; Leukemia, Myeloid, Acute; Male; Nitriles; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Splenectomy; Splenic Infarction; Thalidomide | 2015 |
Autoimmune diseases and myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azacitidine; Comorbidity; Disease Progression; Disease Susceptibility; Female; Follow-Up Studies; Hashimoto Disease; Humans; Immunocompromised Host; Immunosuppressive Agents; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prevalence; Proportional Hazards Models; Retrospective Studies; Thalidomide; Thyroiditis, Autoimmune; Young Adult | 2016 |
Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cell Transformation, Neoplastic; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Registries; Retrospective Studies; Risk Factors; Thalidomide | 2016 |
A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Calcium; Calcium-Binding Proteins; Calpain; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Peptide Hydrolases; Receptors, G-Protein-Coupled; RNA Interference; Thalidomide; Ubiquitin-Protein Ligases | 2016 |
Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.
Topics: Aged; Biomarkers, Tumor; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Janus Kinase 2; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Prognosis | 2017 |
Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Thalidomide; Treatment Outcome | 2009 |
Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 13; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Retrospective Studies; Thalidomide; Trisomy | 2009 |
New agents for the treatment of AML recent study findings.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Carbazoles; Clofarabine; Decitabine; Enzyme Inhibitors; Furans; Humans; Hydrazines; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Quinolones; Staurosporine; Sulfonamides; Thalidomide | 2008 |
Lenalidomide-induced durable hematological and cytogenetic remission in del(5q)-associated de novo acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Thalidomide; Treatment Outcome | 2009 |
CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Recurrence; Thalidomide | 2010 |
Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission.
Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 5; Female; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Remission Induction; Thalidomide; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous | 2010 |
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Erythroid Cells; Female; Follow-Up Studies; Humans; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Thalidomide; Treatment Failure | 2010 |
[Lenalidomide in the treatment of transfusion dependent myelodysplastic syndromes].
Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Risk Factors; Thalidomide; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2010 |
Novel agents for the treatment of acute myeloid leukemia in the older patient.
Topics: Adenine Nucleotides; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quinolones; Thalidomide | 2011 |
Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Remission Induction; Thalidomide; Treatment Outcome | 2011 |
Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Thalidomide | 2012 |
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
Topics: Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; DNA Methyltransferase 3A; Female; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Polymorphism, Single Nucleotide; Prognosis; Thalidomide | 2012 |
Improving the outlook for myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; Disease Progression; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Methyltransferases; Molecular Targeted Therapy; Myelodysplastic Syndromes; Phosphoproteins; Point Mutation; Prognosis; Ribonucleoprotein, U2 Small Nuclear; Risk Assessment; RNA Splicing; RNA Splicing Factors; Spliceosomes; Thalidomide | 2012 |
Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
Topics: Adult; Animals; Antimetabolites, Antineoplastic; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Cytarabine; Frameshift Mutation; Gene Expression Regulation, Leukemic; Humans; Immunologic Factors; K562 Cells; Lenalidomide; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplasm Proteins; Point Mutation; Promoter Regions, Genetic; Protein Isoforms; Protein Structure, Tertiary; Recombinant Fusion Proteins; RNA, Neoplasm; Thalidomide; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Topics: Azacitidine; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Retrospective Studies; Risk; Thalidomide | 2013 |